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Background. Leukotriene B4 (LTB4), a proinﬂammatory lipid mediator correlates well with the acute phase of Acute Respiratory
Distress Syndrome (ARDS). Therefore, LTB4-levels were investigated to determine whether they might be a useful clinical marker
in predicting pulmonary complications (PC) in multiply traumatized patients. Methods. Plasma levels of LTB4 were determined
in 100 patients on admission (ED) and for ﬁve consecutive days (daily). Twenty healthy volunteers served as control. LTB4-
levels were measured by ELISA. Thirty patients developed PC (pneumonia, respiratory failure, acute lung injury (ALI), ARDS,
pulmonary embolism) and 70 had no PC (ØPC). Results. LTB4-levels in the PC-group [127.8pg/mL, IQR: 104–200pg/ml] were
signiﬁcantly higher compared to the ØPC-group on admission [95.6pg/mL, IQR: 55–143pg/mL] or control-group [58.4pg/mL,
IQR: 36–108pg/mL]. LTB4 continuously declined to basal levels from day 1 to 5 without diﬀerences between the groups. The
cutoﬀ to predict PC was calculated at 109.6pg/mL (72% speciﬁcity, 67% sensitivity). LTB4 was not inﬂuenced by overall or chest
injury severity, age, gender or massive transfusion. Patients with PC received mechanical ventilation for a signiﬁcantly longer
period of time, and had prolonged intensive care unit and overall hospital stay. Conclusion. High LTB4-levels indicate risk for PC
development in multiply traumatized patients.
1.Introduction
Trauma patients are at high risk of developing respiratory
complications such as pneumonia, respiratory failure, Acute
Lung Injury (ALI), Acute Respiratory Distress Syndrome
(ARDS), and pulmonary embolism. Following multiple or-
gan failure (MOF) and sepsis, respiratory complications are
among the most common causes of morbidity and mor-
tality for trauma patients surviving the initial postinjury
phase [1–5]. The overall mortality from ARDS is still up to
50% [6–8]. Multiply traumatized patients have shown 10%
mortality following ALI [9]. Approximately 20% of major
trauma admissions develop ARDS or ARDS like pulmonary
dysfunction. This represents one of the most frequent
complications in these patients and is the major contributor
to morbidity and mortality in trauma patients [3, 10, 11].
Several airway diseases including ALI/ARDS are closely
associated with neutrophil inﬁltration of the airway wall
[12]. Neutrophils release a variety of oxidants, as well as
degradative and proteolytic enzymes, which induce lung
inﬂammation with subsequent airway remodelling, micro-
vascular damage, and lung tissue injury [12–14]. Persistence
of neutrophils in the lungs is an important contributing
factor to poor survival [15, 16].
Leukotriene (LT) B4 is a proinﬂammatory lipid medi-
ator derived from the 5-lipoxygenase (5-LO) pathway of
arachidonic acid metabolism [17–20]. LTB4 is a potent
chemoattractant which also exerts leukocyte activating abili-
ties and plays a crucial role in neutrophil migration [21–24].
LTB4 induces neutrophil adherence to endothelial cells,
promotes chemotaxis, stimulates the generation and release
of oxidants, and increases 5-LO activation in neutrophils,
resulting in enhanced LTB4 synthesis [17, 18, 25]. Patients
with pulmonary disease have elevated levels of LTB4 indi-
cating its proinﬂammatory role [25–27]. LTB4 concentra-
tions are enhanced in bronchoalveolar lage (BAL) ﬂuid
of ALI/ARDS and chronic obstructive pulmonary disease
(COPD) patients [27, 28]. Recently, it has been reported
that LTB4 and its metabolites, due to a “priming” eﬀect
on neutrophils, plays an important role in the development2 Mediators of Inﬂammation
of polymorphonuclear-neutrophils-(PMN-) induced lung
injury [29]. The priming eﬀect of sequestered neutrophils
in the lungs leads to their “hyperfunction.” This results in
an exaggerated inﬂammatory cell response to a secondary
stimulus potentially inducing lung complications [30–32].
Earlyidentiﬁcationofhigh-risk patientsforrespiratorycom-
plications after trauma is important in determining subse-
quent treatment. The potential prognostic role of LTB4 in
majortraumapatients,suﬀeringlungcomplicationsinalater
postinjury phase, remains unclariﬁed.
We hypothesize that high levels of LTB4 in the plasma
of multiply traumatized patients indicate not only a strong
proinﬂammatory response, but may also serve to identify
patients at risk for imminent lung complications.
2. Methods
2.1. Ethics. This study was performed in the Goethe Univer-
sity Hospital with ethical approval (167/05, in accordance
with the Declaration of Helsinki and following STROBE-
guidelines) [33]. All patients signed the informed consent
forms themselves or informed consent was obtained from
relatives in accordance with ethical standards.
2.2. Patients. Inclusion criteria consisted of a history of
acute blunt or penetrating trauma with an Injury Severity
Score (ISS) ≥ 16 in any patient between 18 and 80 years of
age. Burns, concomitant acute myocardial infarction, and/or
lethal injury were exclusion criteria.
Blood samples were obtained from 100 multiply trauma-
tized patients on admittance to the emergency department
(ED),anddailyfor5daysfollowingthetrauma.Uponarrival
at the ED, vital signs were documented. Trauma severity was
scored using the Abbreviated Injury Scale (AIS) [34–36].
In addition, ISS was calculated [37]. Patients with an ISS
from 16–24 were classiﬁed as substantially injured patients,
patients with an ISS from 25–39 were substantially/severely
injured patients and patients with an ISS ≥ 40 were
considered severely injured patients.
Pulmonary complications were deﬁned as nosocomial
pneumonia, ALI/ARDS, pulmonary embolism, and/or respi-
ratory failure as described below. Pneumonia was deﬁned by
radiologic, clinical, and bacteriologic ﬁndings with the pres-
ence of new pulmonary inﬁltrates and at least one of the fol-
lowing criteria: positive blood culture, BAL, and/or sputum
culture [38]. Lung injury was assessed using the American-
EuropeanConsensusConferencecriteriaforARDS[39].Pul-
monary embolism was diagnosed by computed tomography
(CT), and pulmonary edema was diagnosed either by CT
scan or chest X-ray. Respiratory failure was deﬁned as the
need for prolonged weaning or reintubation.
The control group included 20 healthy nonsmoking
volunteers with un known chronic disease and no history of
abdominal trauma or abdominal surgery within the past 24
months.
2.3. Blood Processing and Analysis. Blood samples were
collected as early as possible after injury in prechilled eth-
ylenediaminetetraacetic acid (EDTA) vacuum tubes (BD
vacutainer, Becton Dickinson Diagnostics, Aalst, Belgium)
and kept on ice. Blood was centrifuged at 2000 ×gf o r1 5
minutes at 4◦C. The supernatant was stored at −80◦C until
batch sample analysis.
Themeantimebetweentheinjuryandﬁrstbloodsample
taken directly upon admittance to the ED was 83 ± 7min.
Specimens were used for duplicate measurement of LTB4
levels. LTB4 was determined using a highly speciﬁc com-
mercially available ELISA (LTB4 Parameter Assay Kit, R&D
Systems, Minneapolis, USA) according to the manufacturer’s
instructions. The detection limit was 27.6pg/mL for LTB4.
2.4.Statistics. Kolmogoroﬀ-Smirnoﬀ-Lillieford’stestshowed
that the plasma concentration of LTB4 was not Gaussian-
distributed. Median LTB4 levels for each of the 3 groups were
compared using the Kruskal-Wallis test and the post hoc an-
alysis was performed with Dunn’s multiple comparison test.
Data are presented as the median (interquartile range, IQR)
or mean ± sem unless otherwise stated. A P value < 0.05 was
considered statistically signiﬁcant. Receiver-operator curves
weregeneratedtoanalyzetheoptimalcutoﬀlevels.GraphPad
Prism 5.0 software (GraphPad Software Inc. San Diego, CA)
was used to perform the statistical analysis and computa-
tions.
3. Results
The total group consisted of 100 patients (24 female, 76
male), 98% suﬀering from blunt and 2% from penetrating
trauma. All patients were substantially injured (ISS: 34.0 ±
1.7). Of these, 30 patients with an ISS of 33.7±1.6 developed
secondary pulmonary complications. Seventy patients with
an ISS of 34.1 ± 1.3 had no pulmonary complications. The
AISchest w a sc o m p a ra b l ei nb o t hgr o u p s( 3 .1±0.2 in the ØPC
group and 3.5 ± 0.2 in the PC group). Time on mechanical
ventilation, length of stay in the ICU and hospital were
signiﬁcantly prolonged in the PC group. Additionally, more
patients developed sepsis (P<0.05), organ failure, and MOF
in the PC group. In-hospital mortality was also increased.
Table 1 summarizes general patient characteristics and phys-
iologic parameters in the study population. Table 2 depicts
the type, severity, and cause of injury.
Figure 1 shows the distribution of plasma LTB4 values
in the ﬁrst sample obtained in the ED and subsequent daily
measurements for ﬁve consecutive days. Median concentra-
tions (and IQR) of LTB4 in trauma patients on admission
were signiﬁcantly increased compared to healthy controls
(106.1 (62–159)pg/mL versus 58.4 (36–108)pg/mL, P<
0.05, Figure 1). The LTB4 levels on admission were also sig-
niﬁcantly elevated compared with levels at day 1 until day 5.
To investigate the relation between the injury severity
and LTB4 concentrations determined in the ED, the study
population was subdivided into three groups: seriously
injured patients (ISS: 16–24, n = 17), seriously/severely
injured patients (ISS: 25–39, n = 54), and severely injured
patients (ISS: ≥40, n = 29). Plasma LTB4 concentrations in
each group were markedly enhanced (112.8 (68–167)pg/mL,
107.6 (48–164)pg/mL, and 105.3 (62–148)pg/mL, resp.)
compared with healthy volunteers 58.4 (36–108)pg/mL, but
this tendency was not signiﬁcant (Figure 2(a)).Mediators of Inﬂammation 3
Table 1: Summary of patient characteristics and physiologic parameters in the investigated groups (ØPC: no pulmonary complications, PC:
pulmonary complications and ctrl, data are presented as mean ± SEM unless otherwise stated).
Patient characteristics All patients (n = 100) PC (n = 30) ØPC (n = 70) ctrl (n = 20) P value(PC versus ØPC)
Age (years) 39.2 ±1.74 2 .8 ±3.43 7 .9 ±1.93 2 .3 ±2.8 0.2241
Sex (male) 76 20 56 7 —
Injury severity score 34.0 ±1.03 3 .7 ±1.63 4 .1 ±1.3 — 1.0000
Surgery after admission 69.0% 76.7% 70.8% — 0.6218
Thoracic drainage 34.0% 53.3% 25.7% — 0.0191
Packed red blood cells (pRBC)/250mL (24 h) 7.4 ±1.28 .6 ± 1.97 .2 ±1.5 — 0.2739
Massive transfusion (≥10 units pRBC in 24) 20.0% 26.7% 17.4% — 0.6007
Haemoglobin (g/dL) 11.5 ±0.39 .9 ± 0.71 2 .6 ±0.3 — 0.0044
Intubation 73.0% 96.7% 81.4% — 0.0762
Intubation duration (d)9 .9 ±1.11 8 .4 ±2.76 .4 ±0.8— <0.0001
Rotational bed therapy 62.0% 86.7% 51.4% — 0.0020
Rotational bed Therapy (d)3 .9 ±0.55 .3 ± 0.73 .4 ±0.6 — 0.0070
I n t e n s i v ec a r ep e r i o d( d)1 2 .8 ±1.32 2 .4 ±3.18 .9 ±0.9— <0.0001
Hospital stay 24.1 ±2.03 2 .5 ±5.22 0 .5 ±1.7— <0.0001
Sepsis (n/%) 16/16.0% 11/36.7% 5/7.1% — 0.0162
Organ failure (n/%) 8/8.0% 5/16.7% 3/4.3% — 0.3137
MOF (n/%) 4/4.0% 3/10.0% 1/1.4% — 0.4889
Hospital mortality (n/%) 6/6.0% 3/10.0% 3/4.3% — 0.6390
LTB4 (pg/mL, interquartile range) 105.9( 9 6 .7) 127.8( 9 6 .5) 95.6 (88) 58.4( 7 2 .1) 0.0140
Table 2: Overview of type and mechanisms of injuries within the two investigated groups groups (ØPC: no pulmonary complications, PC:
pulmonary complications and ctrl, data are presented as mean ± SEM).
Group All patients (n = 100) PC (n = 30) ØPC (n = 70) P value (PC versus ØPC)
Abbreviated injury severity-scale (AIS, mean ± sem)
AIS head 2.5 ±0.22 .3 ±0.32 .6 ±0.2 0.4332
AIS chest 3.2 ±0.13 .5 ±0.23 .1 ± 0.2 0.1008
AIS abdomen 1.9 ±0.11 .9 ±0.22 .0 ±0.2 0.8208
AIS extremities & external 2.2 ±0.12 .4 ±0.22 .2 ±0.2 0.3601
Mechanism of Injury (n)
Blunt 98 29 69 —
Penetrating 2 1 1 —
Accident mechanism (n/%)
Road accident 69/69.0% 21/70.0% 48/68.6%
Motorcycle 30/30.0% 4/13.32 6 /37.1%
Car 28/28.0% 12/40.0% 16/22.9%
Pedestrian 6/6.0% 4/13.3% 2/2.9%
Bicyclist 5/5.0% 1/3.3% 4/5.7%
Fall 24/24.0% 6/20.0% 18/25.7%
>3m 2 0 /20.0% 6/20.0% 14/20.0%
<3m 4 /4.0% — 4/5.7%
Other 7/7.0% 3/10.0% 4/5.7%
The severity of chest trauma was assessed using the AIS
chest scores. Patients without a relevant chest injury were
graded as AISchest ≤ 2( n = 21). Patients with serious and
serious/severe chest injury (AISchest = 3o r4 )o c c u r r e dm o s t
frequently (n = 23, and n = 49, resp.), whereas patients with
an AISchest = 5o c c u r r e dl e s so f t e n( n = 7). Taken together,
LTB4 levels were increased in all four trauma patient groups
(AISchest ≤ 2: 113.9 (61–162), AISchest = 3: 105.8 (47–200),
AISchest = 4: 107.7 (64–156), and AISchest = 5: 94.9 (65–
133)pg/mL) compared with healthy volunteers, but this
diﬀerence was not signiﬁcant (Figure 2(b)).
However,comparingLTB4levelstakenintheEDofthose
patients who developed pulmonary complications (n = 30)
following injury with those patients who did not develop
pulmonary complications (n = 70) and healthy volunteers
revealed a signiﬁcant diﬀerence (127.8 (104–200) versus4 Mediators of Inﬂammation
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Figure 1: Summary of median (interquartile range) LTB4 (pg/mL)
in multiply traumatized patients over a 5-day time course after
admission (n = 100), and ctrl (n = 20).
∗P < 0.05 versus other
groups.
95.6 (55–143) and 58.4 (36–108)pg/mL, resp., P<0.05,
Figures 3(a) and 3(b)). Follow-up LTB4 levels (day 1–day 5)
showed that increased LTB4 levels in the ED in patients with
pulmonary complications diminished in a time-dependent
manner (Figure 3(a)). This eﬀect was irrespective of the
patients ISS or AISchest since subgroup analysis according to
ISS or AISchest revealed no diﬀerences in LTB4 levels.
Receiver operating characteristics (ROCs) analysis for
LTB4 shows an optimal cutoff of 109.6pg/mL with 72% spe-
ciﬁcity (95% CI: 0.61–0.81) and 67% sensitivity (95% CI:
0.49–0.84),forpredictingpulmonarycomplicationsinalater
posttraumatic course (Figure 4). The area under the ROC
curve is 0.73.
Multiply traumatized patients with pulmonary compli-
cations needed signiﬁcantly prolonged mechanical ventila-
tion compared with patients without secondary pulmonary
complications (18.4±2.7da ysv ersus6.4±0.8days,resp.,P<
0.05, Table 1). The mean ICU stay of all patients was 12.8 ±
1.3 days. Patients with pulmonary complications had a mean
ICU stay of 22.4 ± 3.1d a y sv e r s u s8 .9 ± 0.9 days in patients
without pulmonary complications (P<0.05, Table 1). Pa-
tients with pulmonary complications also had signiﬁcantly
prolonged hospital stay compared with patients without pul-
monary complications (32.5 ± 5.2d a y sv e r s u s2 0 .5 ± 1.7
days, resp., P<0.05, Table 1). Sixteen patients developed
sepsis, of those 69% had pulmonary complications (Table 1).
Eight patients suﬀered from organ failure, and 4 patients had
MOF, of those 63% and 75%, respectively, had pulmonary
complications (Table 1). The mortality rate was enhanced
for patients with pulmonary complications (10%) com-
pared with patients without pulmonary complications (4%,
Table 1).
4. Discussion
Respiratory complications, such as pneumonia, respiratory
failure, ALI/ARDS, and pulmonary embolism are, next to
MOF and sepsis, among the most common causes of late
morbidityandmortalityaftertrauma[1–5,40].Anincreased
rate of pulmonary complication in severely injured trauma
patients is closely associated with an excessive systemic and
local inﬂammatory response including neutrophil inﬂux
[12, 40–42]. LTB4 represents a potent neutrophil chemoat-
tractant and enhanced LTB4 levels are associated with pul-
monary disease [25–28]. Despite the close association with
airway disease, it remains unclear whether LTB4 is a reliable
parameter for early identiﬁcation of high-risk patients for
pulmonary complications after multiple trauma.
This study shows that multiply traumatized patients with
high LTB4 levels (cutoﬀ at 109.6pg/mL) in the initial phase
are at high risk to develop posttraumatic pulmonary com-
plications. The association of increased LTB4 in BAL ﬂuid
of patients with ALI/ARDS and COPD has previously been
reported [27, 28]. The majority of clinical studies focused on
the proinﬂammatory role of LTB4 in neutrophil inﬁltration
and the subsequently induced lung injury in ICU patients
[27–32]. The decisive role of neutrophils in several airway
diseases, including ALI/ARDS, has been described [12–14].
Their persistence in the lungs is closely associated with poor
survival [15, 16].
LTB4 is biosynthesized from arachidonic acid by the
action of cytosolic phospholipase A2, 5-LO together with 5-
LO-activating protein (FLAP) and leukotriene A4 hydrolase
[43]. 5-LO activity is considered a key factor in LTB4 biosyn-
thesis. LTB4 levels have been shown to correlate with tumor
necrosis factor alpha levels and the number of neutrophils
recovered from the BAL ﬂuid of patients with ARDS [44].
Furthermore, LTB4 and its metabolites have been shown
to cause increased neutrophil adherence to the pulmonary
endothelial cell surface, reﬂecting neutrophil sequestration
in the lung and the capillary bed and increasing vascular per-
meability [17, 29, 45, 46]. Inhibiting the 5-LO rate-limiting
enzyme in LTB4 biosynthesis by intratracheal application of
IL-8 has been shown to prevent lung injury and perfusate
LTB4 increase in the lungs. Neutrophil chemotaxis in vitro
was also inhibited [47]. Therefore, it might be concluded
thatthe impact ofenhancedsystemicLTB4concentrations in
trauma patients presenting at the ED may reﬂect an ongoing
systemic inﬂammation. This, in turn, may lead to the devel-
opment of pulmonary complications. Therefore, the predic-
tive relevance of LTB4 should be considered in this highly
heterogeneous group of patients. Employing timely appro-
priate treatment (e.g., kinetic therapy, operative and ventila-
tory strategies) could thereby improve patient outcome.
Other factors have been reported to be associated with
the development of posttraumatic pulmonary complica-
tions. The extent of chest trauma has been shown to increase
respiratory complications, such as ALI/ARDS [48, 49]. In-
erestingly, we found no signiﬁcant correlation between the
degree of chest injury assessed by the AIS and the rate of
posttraumatic pulmonary complications. This may be due
to the study having been conducted at a single clinic with
a limited number of patients (n = 100). In a multivariate
statisticalanalysis,wefoundthattheeﬀectoftraumaseverity
on LTB4 levels as well as the development of pulmonary
complicationsisconsiderednotsigniﬁcant(datanotshown).Mediators of Inﬂammation 5
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Figure 2: Summary of median (interquartile range) LTB4 (pg/mL) in ED samples in diﬀerent groups of patients based on the overall injury
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Figure 3: Summary of median LTB4 (pg/mL) in two patient groups based on the development of pulmonary complications (ØPC: no
pulmonary complications, n = 70, and PC: pulmonary complications, n = 30) and ctrl, n = 20,
∗P < 0.05 versus other groups: (a) time
course in both groups, (b) LTB4 levels at the ED.
Evaluation of data from patients with hypoxemic respiratory
failure (n = 8) has shown that LTB4 levels (at ED) were
signiﬁcantly enhanced in this group compared to healthy
volunteers, but did not diﬀer markedly from 22 patients with
nonhypoxemic respiratory complication (data not shown).
In the present study, the mortality was 6% in a cohort of
trauma patients with considerable injury (mean ISS > 33).
Blunt trauma as the major type of injury in over 90%
of patients was in accordance with other European studies
[50, 51]. Dysregulated immune response after trauma has
been suggested to contribute to complications, such as sepsis
and MOF. The incidence of sepsis and MOF vary strongly in
the literature[2, 52–56]. In the present study, sepsis occurred
in 16% and MOF in only 4% of patients. In line with the
literature, trauma patients with pulmonary complications
constitute the majority of patients who develop sepsis and/or
MOF [52]. Interestingly, in the present study, patients de-
veloping pulmonary complications were not more severely
injured than patients without pulmonary complications, as
h a db e e ne x p e c t e df r o mp r e v i o u sr e p o r t s[ 52]. The clinical
course was strongly aﬀected by the presence of respiratory
complication with a prolonged ICU stay, days on mechanical
ventilation, and longer hospital stay.
Pulmonary complications after severe trauma markedly
aﬀect the clinical course. The predisposing factors for these
patients at risk are not fully understood and their identiﬁca-
tion before clinical manifestation of complications remains a
challenge. Most clinical scoring systems have been developed
to compare populations, while their predictive power is
limited. The lung organ failure scoring (LOFS) method
has been developed to estimate the risk for pulmonary
complications in trauma patients [57]. Its eﬀectiveness still
needs to be assessed in prospective clinical studies.
In conclusion, to stratify the risk for later pulmonary
complications the results presented here encourage LTB4
assessment early after trauma. In the present study, the LTB46 Mediators of Inﬂammation
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Figure 4: Receiver operating curve showing the optimal cutoﬀ for
LTB4 levels (109.6pg/mL in predicting the presence or absence of
postinjury pulmonary complications with 72% speciﬁcity and 67%
sensitivity).
AUC is quite small. Enhanced patient numbers, especially in
the group of patients with pulmonary complications, could
strengthen the hypothesis that LTB4 may be of predictive
value. While the pathophysiological sequelae of increased
LTB4 release is principally understood, identiﬁcation of rel-
evant eﬀects such as neutrophil adherence or edema forma-
tion need demonstration in the clinical setting. Therefore,
clinical studies with larger numbers of patients are required
to clarify the role of LTB4 in pulmonary complications and
resolve its predictive eﬃcacy.
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